熱門資訊> 正文
BRIEF-Aduro Biotech Presents Nonclinical, Phase 1 Healthy Volunteer Data For BION-1301
2020-06-02 19:39
June 2 (Reuters) - Aduro Biotech Inc :
* ADURO BIOTECH PRESENTS NONCLINICAL AND PHASE 1 HEALTHY VOLUNTEER DATA FOR BION-1301 AT THE 57TH ERA-EDTA VIRTUAL CONGRESS
* ADURO BIOTECH INC - BION-1301 WAS WELL-TOLERATED, WITH NO SERIOUS ADVERSE EVENTS
* ADURO BIOTECH INC - PHARMACOKINETICS OF BION-1301 WERE GENERALLY DOSE-PROPORTIONAL WITH AN ESTIMATED HALF-LIFE OF 33 DAYS
* ADURO BIOTECH INC - BION-1301 DOSE-DEPENDENTLY AND DURABLY REDUCED IGA AND IGM
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
